These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19306511)

  • 41. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
    Cho WI; Chang UK
    J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
    Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
    J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
    Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
    Gerbaudo VH; Sugarbaker DJ; Britz-Cunningham S; Di Carli MF; Mauceri C; Treves ST
    J Nucl Med; 2002 Sep; 43(9):1144-9. PubMed ID: 12215551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.
    Nishiyama Y; Yamamoto Y; Kimura N; Ishikawa S; Sasakawa Y; Ohkawa M
    Ann Nucl Med; 2008 May; 22(4):245-50. PubMed ID: 18535874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions.
    Laffon E; de Clermont H; Begueret H; Vernejoux JM; Thumerel M; Marthan R; Ducassou D
    Nucl Med Commun; 2009 Jun; 30(6):455-61. PubMed ID: 19381115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
    Ambrosini V; Rubello D; Nanni C; Farsad M; Castellucci P; Franchi R; Fabbri M; Rampin L; Crepaldi G; Al-Nahhas A; Fanti S
    Nucl Med Rev Cent East Eur; 2005; 8(2):111-5. PubMed ID: 16437396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
    Zhuang H; Pourdehnad M; Lambright ES; Yamamoto AJ; Lanuti M; Li P; Mozley PD; Rossman MD; Albelda SM; Alavi A
    J Nucl Med; 2001 Sep; 42(9):1412-7. PubMed ID: 11535734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
    Sørensen JB; Ravn J; Loft A; Brenøe J; Berthelsen AK;
    Eur J Cardiothorac Surg; 2008 Nov; 34(5):1090-6. PubMed ID: 18799318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
    Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
    J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma.
    Lopci E; Novellis P; Testori A; Rahal D; Voulaz E; Bottoni E; Ferraroli GM; Crepaldi A; Ceresoli GL; Perrino M; Castello A; Alloisio M; Veronesi G; Zucali PA
    Nucl Med Commun; 2019 Nov; 40(11):1179-1186. PubMed ID: 31568271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.
    Huang YC; Tu DG; Wu JD; Lee MY
    Spine (Phila Pa 1976); 2009 Oct; 34(21):E780-3. PubMed ID: 19934799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
    Wilcox BE; Subramaniam RM; Peller PJ; Aughenbaugh GL; Nichols Iii FC; Aubry MC; Jett JR
    Clin Lung Cancer; 2009 Jul; 10(4):244-8. PubMed ID: 19632941
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
    Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
    J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual-time-point FDG PET/CT: Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer?
    Kim DW; Kim WH; Kim CG
    Nucl Med Mol Imaging; 2012 Sep; 46(3):196-200. PubMed ID: 24900060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
    Lococo F; Rena O; Torricelli F; Filice A; Rapicetta C; Boldorini R; Paci M; Versari A
    Interact Cardiovasc Thorac Surg; 2020 Apr; 30(4):593-596. PubMed ID: 32003806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
    Tan C; Barrington S; Rankin S; Landau D; Pilling J; Spicer J; Cane P; Lang-Lazdunski L
    J Thorac Oncol; 2010 Mar; 5(3):385-8. PubMed ID: 20087231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
    J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.